Nektar Therapeutics NKTR

$37.76 +0.81 (2.19%)

Valuation

Market cap
1,261,584,000
Revenue TTM
$55,230,000
Net income TTM
$-164,080,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-297.08%
Debt to equity
0.00

Trading

Volume
428,800
Avg volume
1,234,464
Day's range
$37.28 – $38.46
Shares out
34,143,000
Stochastic %K
34%
Beta
1.45
Analysts
Moderate Buy
Price target
$126.38

Price

Company profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat...

Show more

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Phone
415 482 5300
Website
https://www.nektar.com
Address
455 Mission Bay Boulevard South, San Francisco, United States

Latest news

Stocktwits

BK217 Nov 3, 1:06 AM
$NKTR I have really come to enjoy all these days of constant fingering. Reminds of 2023/2024/H12025
0 replies
Merlintrader Oct 31, 11:37 PM
$NKTR closed the week at $38.87 (+4.4% w/w, -0.8% Friday), below the 50-day SMA ($55.69) and below the 200-day ($65.01). RSI14 34.7. Support $35.61, resistance $43.57 (20-day range, middle). Broad market sell-off on Friday. New hub updated: https://www.merlintrader.com/nektar-therapeutics-stock-hub/
0 replies
Merlintrader Oct 27, 6:29 AM
$NKTR finished Monday at $37.45, below both the 50-day SMA ($58.53) and the 200-day ($63.94), at the low end of its 20-day range ($35.61-$62.40). Daily RSI 30. $SPY $XBI Interactive chart with bull and bear scenarios, support/resistance and trendlines on JC Just Charts: https://justcharts.merlintrader.com/#NKTR Not investment advice.
0 replies
BK217 Oct 24, 4:25 PM
$NKTR first and last!
0 replies
FlashAim Oct 23, 7:05 PM
Join Starlight ⬇️ Easily the best small-cap community I’ve found It’s completely free to join for now, but access is limited💠 Watching||8 $NKTR $VWAV $ARTV
0 replies
NON_FICTION_1 Oct 20, 4:22 PM
$NKTR 👈🚀they never
1 replies
NON_FICTION_1 Oct 20, 1:49 PM
$NKTR $MDGL boring … but both will go higher
0 replies
NON_FICTION_1 Oct 19, 7:30 PM
$NKTR tutes own 103% … Im buying here in the $36 s … you wiil know soon enough.
1 replies